Clinical Immunology and Immunopathology
Volume 73, Issue 2, November 1994, Pages 180-186
Regular ArticleSuppression of Cytokine-Dependent Human T-Cell Proliferation by Intravenous Immunoglobulin
References (0)
Cited by (134)
Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study
2021, Clinical Microbiology and InfectionImmunoglobulin Therapy
2016, Pediatric Allergy: Principles and Practice: Third EditionIVIg prevents the in vitro activation of T cells by neutralizing the T cell activators
2013, Immunology LettersCitation Excerpt :However, because IVIg contains anti-mouse IgG reactivity [32], it can be speculated that at least some IVIg binds to anti-CD3 and anti-CD28 on the beads. This finding is of importance considering that anti-CD3 antibodies, in combination or not with anti-CD28, have been commonly used to determine the effect of IVIg on T cells [25,26,33]. In these studies, the authors concluded that IVIg inhibits the function of activated T cells (proliferation, cytokine secretion or expression of activation markers such as CD25 or CD69).
Mechanisms of action of intravenous immunoglobulins
2012, Bulletin de l'Academie Nationale de Medecine
Copyright © 1994 Academic Press. All rights reserved.